We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Since rolling out its pulsed field ablation system for treating atrial fibrillation earlier this year, Boston Scientific has ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific (BSX – Research Report). The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Canaccord Genuity analyst William Plovanic has maintained their bullish stance on BSX stock, giving a Buy rating today. William Plovanic has ...

Boston Scientific Corp. (BSX) on Wednesday reported third-quarter earnings of $469 million. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 32 cents.

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

WASHINGTON, D.C.—Boston Scientific’s long-awaited transcatheter aortic heart valve missed its mark in a head-to-head study aimed at bringing the implant to the U.S.—but the company believes ...

The company said its trial is the only one to study using a Pulsed Field Ablation System as a first-line treatment for persistent AF. The company has temporarily paused enrollment until it better ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...